Sequencing a human genome cost about $100 million in 2001. Today it costs under $200, a drop of more than five orders of magnitude, tracked by the NHGRI. That collapse is one of the great achievements of modern science, and it has opened the door to research and diagnostics that were unthinkable a decade ago. It has also moved the hard part downstream: the science your lab can do is increasingly limited not by sequencing, but by how quickly raw data becomes an answer.
The scale behind that shift is staggering, and it is a measure of how far the field has come. Sequenced data has doubled roughly every seven months, and genomics was projected to consume between 2 and 40 exabytes of storage by 2025. Cloud and hybrid platforms already process more than 480 petabases of raw sequencing output a year, equivalent to about 5 million whole genomes.
This guide explains what an NGS data analysis platform is, why analysis is now the constraint, the levers that let labs scale faster, whether to build or buy, and where scaling efforts go wrong, so your team spends more of its time on the science only it can do.
What is an NGS data analysis platform?
An NGS data analysis platform is the software and infrastructure that turns raw sequencer output into interpreted, reportable results. It spans three stages: primary analysis (base calling on the instrument), secondary analysis (alignment and variant calling), and tertiary analysis (annotation, classification, and interpretation).
A platform differs from a single pipeline because it orchestrates execution, scaling, data management, quality control, and delivery across many samples and assay types, so scientists can focus on the questions the data is meant to answer rather than the mechanics of processing it.
Why analysis, not sequencing, is the bottleneck now
When the sequencer was an expensive, slow step, labs optimized around it. That constraint is gone, and the work now accumulates downstream, around the science rather than within it.
As sample volume grows, the lab's most valuable resource, the time and judgment of its scientists and bioinformaticians, gets pulled away from research and interpretation and into operational work that infrastructure should be handling.
A few things create that drag as volume grows:
- Pipelines that need a specialist to launch every run, check each output, and recover from failures, turning expert bioinformaticians into operators spending hours on plumbing instead of biology.
- Static compute that sits idle between runs and stalls during peaks.
- Compounding storage costs, since each sequenced genome carries roughly tenfold more intermediate data through alignment and variant calling.
- Fragile reproducibility as tool versions and parameters drift between runs, which matters deeply in a regulated lab.
- Scarce bioinformatics talent whose attention is far too valuable to spend supervising compute jobs.
The result is rising turnaround time (TAT) and rising cost per sample at exactly the moment the lab is trying to expand the science it can do. The goal of scaling is not to do without people. It is to give expert people their time back.
The levers that let labs scale NGS analysis faster
Scaling is not one decision. It is a set of engineering choices, each aimed at removing a source of friction between scientists and their results.
| Bottleneck | Scaling lever | Representative tools |
|---|---|---|
| Manual, brittle workflows | Portable workflow orchestration | Nextflow (DSL2) + nf-core, WDL, Snakemake |
| Fixed or idle compute | Elastic cloud with auto-scaling | Kubernetes (EKS/GKE/AKS), AWS Batch, spot instances |
| Slow secondary analysis | Accelerated variant calling | DRAGEN, DeepVariant, NVIDIA Parabricks |
| Repetitive launch and triage | Sequencer-to-pipeline automation | LIMS integration, automated QC gating |
| Version and parameter drift | Containerized, versioned pipelines | Docker, Singularity, audit trails |
| Cost and failures invisible | Observability and cost tracking | Per-sample dashboards, retry logic |
Workflow orchestration is the foundation. Moving pipelines into Nextflow, WDL, or Snakemake makes them portable, parallelizable, and reproducible, and community standards like nf-core give teams validated, peer-maintained workflows so they build on the field's collective work instead of bespoke scripts.
Elastic cloud compute matched to workload through Kubernetes auto-scaling, with spot or preemptible instances, removes both idle capacity and queue delays while cutting cost. Accelerated secondary analysis matters because tools like Illumina's DRAGEN and NVIDIA Parabricks compress alignment and variant calling from hours to minutes through hardware acceleration and algorithmic optimization, and AI-assisted pipelines are shortening analysis run-times by double-digit percentages.
Automation closes the loop, parsing sample sheets on run completion, applying QC gating, and delivering results to LIMS and reporting systems, freeing scientists from repetitive operational steps so their attention goes to interpretation and discovery. Reproducibility comes from containers and immutable per-run records of tool versions, parameters, and reference builds, which protects the scientific integrity of every result. And observability with cost-per-sample tracking turns scaling from guesswork into a managed metric.
Build vs buy: should your lab build its own NGS platform?
This is the decision most lab leaders are really asking about. The market splits almost evenly: in-house analysis held about 58.7% of the NGS data analysis market in 2024, while outsourced analysis is the fastest-growing segment, and cloud-native platforms are expanding quickly among labs with limited bioinformatics staff.
- Fast to deploy and well-suited to standard assays (DRAGEN, Illumina Connected Analytics, Seqera, cloud genomics services).
- Cost at scale can grow significantly as sample volume increases.
- Limited control over custom workflows, with potential vendor lock-in.
- Full control and the freedom to encode novel scientific methods directly into the pipeline.
- Demands scarce talent in bioinformatics and infrastructure engineering.
- Ongoing maintenance is where timelines most often slip.
A third path, increasingly common, is a custom platform engineered on open standards (Nextflow, Kubernetes, your cloud) and either run by your team or operated as a managed service, which keeps scientific control without consuming your scientists in DevOps. The right answer depends on assay complexity, sample volume, regulatory requirements, and how much of your team's time you want protected for science rather than infrastructure.
Where scaling goes wrong
Scaling NGS analysis fails in predictable ways. Getting ahead of these is what separates a platform that holds up under volume from one that quietly accumulates risk.
Runaway cloud cost when pipelines are lifted into the cloud without a spot-instance strategy or cost monitoring, and the bill arrives before the savings.
Reproducibility drift when scaling is bolted onto unversioned pipelines, breaking the audit trail a CAP or CLIA inspection depends on, and with it the scientific defensibility of the results.
Skipped validation, so a faster pipeline ships without benchmarking against reference data like GIAB or SEQC2, trading speed for calls a scientist cannot trust.
Silent pipeline failures, with errors surfacing days later in a clinical report rather than at runtime.
Vendor lock-in that quietly removes a lab's ability to adapt its methods as the science advances.
Each of these is an engineering decision made too late, which is why scaling is best designed in from the start, in service of the work the lab exists to do.
NonStop's approach: how to scale NGS analysis without the infrastructure overhead
The order matters: choose the workflow framework, build for elastic cloud execution and reproducibility, automate the sequencer-to-result path, then add observability and cost control. Most labs try to scale the pipeline they already have and inherit its limits.
This is the engineering NonStop.io Technologies builds for clinical labs, research institutions, biobanks, and genomics scale-ups, with one purpose: to put scientists' time back where it belongs, on research, interpretation, and discovery.
Production-grade NGS pipelines built in Nextflow, WDL, and Snakemake for WES, WGS, RNA-Seq, targeted panels, and somatic and germline variant calling.
Pipelines run on auto-scaling Kubernetes infrastructure (EKS, GKE, AKS) with spot-instance cost optimization and automatic failure recovery on AWS, GCP, or Azure.
GATK HaplotypeCaller, DeepVariant, Mutect2, and Strelka2, benchmarked against SEQC2 and NIST GIAB before clinical deployment, with annotation against gnomAD, ClinVar, COSMIC, and OncoKB.
Every run is automated from sequencer to LIMS with HL7 FHIR result delivery, and for teams whose pipeline output feeds downstream interpretation, the genomics solutions practice connects execution to AI-assisted variant classification and clinical reporting, always leaving the scientific judgment with the experts.
Across engagements, NonStop.io reports turnaround and cost improvements at this scale, the kind of headroom that lets a team take on more science, not less.
Frequently Asked Questions
What is an NGS data analysis platform?
How can labs reduce NGS turnaround time?
What is the difference between secondary and tertiary analysis?
Should a lab build or buy an NGS data analysis platform?
What tools are used to scale NGS pipelines?
Are NGS data analysis platforms HIPAA compliant?
Talk to NonStop.io
Book the Architecture Review
If your sequencers are outrunning your pipeline, the useful next step isn't a demo. It's an honest look at your assay mix, your sample volume, your current compute environment, and where turnaround and cost are pulling your scientists away from their work. NonStop.io runs a 45-minute architecture review for exactly that: no pitch, just a working assessment of your pipeline bottlenecks and a scoped path to scale the science. Book the review and bring your current turnaround numbers.
Book the 45-Minute Review →